Publications by authors named "Kristine Duly"
Article Synopsis
- The study reviews the pharmacologic and clinical profile of adalimumab-adbm, the first interchangeable biosimilar for treating inflammatory diseases like Crohn's disease and rheumatoid arthritis.
- Approval for adalimumab-adbm was based on phase 3 VOLTAIRE trials that showed it has comparable efficacy and safety to the reference drug, with common side effects including infections and injection site reactions.
- This biosimilar aims to improve patient access and reduce costs, though it won't be available until 2023 and may encounter adoption challenges similar to other biosimilars.*
COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations.
Am J Health Syst Pharm
January 2022
Purpose: While COVID-19 vaccine emergency use authorization (EUA) deemed the vaccines to be effective and safe for public use, the phase 3 trials leading to EUA predominantly excluded patients with immunocompromising conditions. Immunocompromised patients make up a significant proportion of the population, and in light of recent mass vaccination efforts, we aim to review current evidence and recommendations of COVID-19 vaccines in 4 patient populations with immunocompromising disorders or conditions: human immunodeficiency virus (HIV) infection, solid organ transplantation, rheumatoid arthritis, and inflammatory bowel disease.
Summary: Given the evolving data on the safety and efficacy of the approved COVID-19 vaccines in the immunocompromised population, it is vital that pharmacists and other immunizing providers understand the current data and recommendations and provide the public with accurate information.